Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Losartan Potassium (formerly DuP-753; MK-954; DuP753; MK954; Cozaar; Lorzaar; Losaprex), the potassium salt of losartan, is an oral, selective, and non-peptide angiotensin II receptor antagonist approved as an antihypertensive drug. It is an AT II antagonist that competes with angiotensin II for binding to AT1 receptors with IC50 of 20 nM.
ln Vitro |
Angiotensin II and losartan potassium compete with one another to bind to AT1 receptors. Twenty nM is the quantity that inhibits angiotensin II binding by 50% (IC50) [1]. ISC is impacted by losartan potassium (40 μM), while ANGII's impact on ISC is inhibited [2]. In endometrial cancer cells, lossartan potassium dramatically inhibits Ang II-mediated cell growth. When Losartan potassium and anti-miR-155 were taken together, the antiproliferative impact was noticeably greater than when either medication was taken alone [3].
|
||
---|---|---|---|
ln Vivo |
Compared to Fbn1C1039G/+ mice treated with a placebo, distal airspace aperture was smaller in mice treated with losartan potassium (0.6 g/L, po). Propranolol and losartan potassium dosage titrations for similar hemodynamic effects. Losartan potassium antagonized TGF-β signaling in the aorta wall of Fbn1C1039G/+ mice, according to pSmad2 nuclear staining studies. The improvement of pulmonary disease symptoms by losartan potassium does not seem to be connected to better hemodynamics [4]. An intra-arterial injection of losartan potassium (10 mg/kg) raises blood angiotensin levels four to six times. Plasma renin levels are increased 100-fold by losartan potassium (10 mg/kg, ip); plasma angiotensinogen levels fall to 24% of control; and plasma aldosterone levels remain unchanged [5].
|
||
Animal Protocol |
|
||
References |
[1]. Burnier, M. Angiotensin II type 1 receptor blockers. Circulation, 2001. 103(6): p. 904-12.
[2]. Ashry, O., et al. Evidence for expression and function of angiotensin II receptor type 1 in pulmonary epithelial cells. Respir Physiol Neurobiol, 2014. [3]. Choi, C.H., et al. Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol, 2012. 126(1): p. 124-31. [4]. Habashi, J.P., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 2006. 312(5770): p. 117-21. [5]. Campbell, D.J., et al. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol, 1995. 26(2): p. 233-40 |
Molecular Formula |
C22H23CLKN6O
|
|
---|---|---|
Molecular Weight |
462.01
|
|
CAS # |
124750-99-8
|
|
Related CAS # |
Losartan Carboxylic Acid;124750-92-1;Losartan-d4 (carboxylic acid);1246820-62-1;Losartan;114798-26-4;Losartan-d4;1030937-27-9
|
|
SMILES |
OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=N[N-]N=N4)C=C2.[K+]
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (216.92 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
Solubility in Formulation 2: Saline:30 mg/mL  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1645 mL | 10.8223 mL | 21.6446 mL | |
5 mM | 0.4329 mL | 2.1645 mL | 4.3289 mL | |
10 mM | 0.2164 mL | 1.0822 mL | 2.1645 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.